Shinya Ueda

Randomized, Open-Label, Phase III Study Comparing Irinotecan With Paclitaxel in Patients With Advanced Gastric Cancer Without Severe Peritoneal Metastasis After Failure of Prior Combination Chemotherapy Using Fluoropyrimidine Plus Platinum: WJOG 4007 Trial

Shuichi Hironaka, Shinya Ueda, Hirofumi Yasui et al. · Journal of Clinical Oncology · 2013 · 548 citations

Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G)

K. Yamazaki, Michitaka Nagase, H Tamagawa et al. · Annals of Oncology · 2016 · 274 citations · Full text

Gastrointestinal Oncology, Medicine, Pharmacology +9

Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial

Kohei Shitara, Atsuo Takashima, Kazumasa Fujitani et al. · ˜The œLancet. Gastroenterology & hepatology · 2017 · 215 citations

Gastrointestinal Oncology, Medicine, Advanced Gastric Cancer +5

Phase I Study of YM155, a Novel Survivin Suppressant, in Patients with Advanced Solid Tumors

Taroh Satoh, Isamu Okamoto, Masaki Miyazaki et al. · Clinical Cancer Research · 2009 · 175 citations

Phase I Safety, Pharmacokinetic, and Biomarker Study of BIBF 1120, an Oral Triple Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors

Isamu Okamoto, Hiroyasu Kaneda, Taroh Satoh et al. · Molecular Cancer Therapeutics · 2010 · 94 citations · Full text

Oncology, Medicine, Malignant Blood Disorder +14